Navigation Links
Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis
Date:10/19/2011

ed for up to eight years of treatment.

About TEMSO study

TEMSO was a two-year randomized, double-blind, placebo-controlled multinational study that included 1,088 people with relapsing forms of MS from 126 centers in 21 countries. Trial participants were 18-55 years of age, with an Expanded Disability Status Scale (EDSS) of 5.5 or less, and had at least one relapse in the previous year or at least two relapses in the preceding two years. Trial participants were randomized to placebo or teriflunomide, 7mg or 14mg, once daily and followed for 108 weeks. The primary endpoint was annualized relapse rate, defined as the number of confirmed relapses per trial participant year; a relapse is a new or worsening of a previous clinical sign or symptom. The key secondary endpoint was the time to sustained disability progression, measured by the EDSS.  Disability progression was defined as an increase from baseline of at least 1.0 point on the EDSS persisting for at least 12 weeks. Change from baseline in total lesion volume was also a key prespecified MRI endpoint in the study. Safety and tolerability evaluations were based on adverse events, physical examinations, vital signs and laboratory investigations. A long-term extension of TEMSO is ongoing.

About Teriflunomide

Teriflunomide is an immunomodulatory, disease-modifying oral drug with anti-inflammatory properties, and is under investigation for the treatment of relapsing forms of MS. Teriflunomide blocks the proliferation and functioning of activated T and B lymphocytes - which are thought to be especially damaging in MS - by selectively and reversibly inhibiting a critical mitochondrial enzyme. With nine years of continuous use in a Phase II extension, teriflunomide has the longest clinical experience of any investigational oral MS therapy. In addition to the TEMSO trial, two other Phase III trials, TOWER and TENERE, are ongoing in people with RMS. A Phase III study, TOPIC, is also underway
'/>"/>

SOURCE Sanofi
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Progenitor Cell Therapy, a Wholly-Owned Subsidiary of NeoStem, Inc., Announces Additions to Management
2. NeoStem Acquires Amorcyte, a Clinical Stage Cardiovascular Disease Cell Therapy Company
3. New Findings Reported by TJ Gan and Authors from Duke Anesthesiology Demonstrate Efficacy of Cheetah Medicals NICOM® Bioreactance® Technology to Guide Goal Directed Intraoperative Therapy
4. Antigen Express to Present at Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference at the New York Academy of Medicine
5. KGI Professor Awarded Patent for Stem-Cell Therapy Aiding Heart-attack Patients
6. NORTHWEST BIO Will Present at the Second Annual "Cancer Immunotherapy: A Long Awaited Reality Conference" at the New York Academy of Medicine, October 6, 2011
7. EGEN, Inc. Collaborates With Nanotechnology Characterization Laboratory on Brain Cancer Therapy
8. SanBio Announces Site Opening of Phase 1/2a Clinical Trial of Novel Cell Therapy in Stable Stroke Patients at University of Pittsburgh Medical Center
9. Antigen Express Cancer Vaccine Highlighted in Expert Opinion on Biological Therapy
10. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
11. Immune Deficiency Foundation Launches Free Accredited Course for Nurses About Primary Immunodeficiency and Immunoglobulin Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  Decision Resources ... Brazil and Mexico ... uptake of several newly approved agents, the anticipated ... indication and the launch of emerging biologics will ... In particular, the emerging IL-5 inhibitors will introduce ...
(Date:8/21/2014)... Cord Blood Corporation (NYSE: CO ) (the ... for the first quarter of fiscal year 2015 on ... US.  The Company will host a ... 29, 2014 to discuss its financial performance and give ... by a question and answer session.  Interested parties may ...
(Date:8/21/2014)... 21, 2014 Ontotext S4 , ... Ontotext . Now the same enterprise hardened ... structured and unstructured data is available to start-ups and ... enterprise technology. Organizations that do not have resources to ... can use S4 since there is no need for ...
(Date:8/21/2014)... August 21, 2014 On Wednesday of last ... to use Redox Signaling molecules, became available for purchase in ... , "The way that RENU 28 works is, if you ... down of the rate of cellular renewal within your body. ... increasing of that rate of cellular renewal. What RENU 28 ...
Breaking Biology Technology:Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4RENU 28 Skin Care Now Available in Australia and New Zealand 2
... 16, 2011 Genesis Biopharma, Inc. (OTC ... developing targeted cancer therapies, today announced it is expanding ... various cancers.  The Company will focus on establishing a ... new strategy will be discussed during a presentation today ...
... SAN DIEGO, March 15, 2011 PR Newswire, ... solutions, today announced the extension of their exclusive ... be the preferred provider of content distribution services ... science association. (Logo: http://photos.prnewswire.com/prnh/20000306/PRNLOGO) ...
... Biotechnology company ImmusanT, Inc. today announced it ... is advancing its strategy to develop an immunotherapeutic ... disease. The company completed the acquisition of a ... Ltd., based in Melbourne, Australia, and secured seed ...
Cached Biology Technology:Genesis Biopharma Announces Plans to Develop Active Immunotherapy Platform 2PR Newswire and BIOCOM Purchasing Group Announce Renewal of Exclusive Partnership 2PR Newswire and BIOCOM Purchasing Group Announce Renewal of Exclusive Partnership 3Start-Up ImmusanT Seeks to Restore Tolerance to Gluten in Celiac Disease with Immunotherapy 2Start-Up ImmusanT Seeks to Restore Tolerance to Gluten in Celiac Disease with Immunotherapy 3Start-Up ImmusanT Seeks to Restore Tolerance to Gluten in Celiac Disease with Immunotherapy 4
(Date:8/22/2014)... the 29th Annual International Papillomavirus Conference shows that ... combats three types of human papillomavirus, including the ... cancer. , When tested in several cultured human ... HPV-18 and HPV-11 cells, according to Louise T. ... the findings at the Seattle conference. The National ...
(Date:8/22/2014)... can probably remember the after-effects, including pain, swelling or ... back against the injury. When tissue in the body ... tissue regeneration. An inflammatory response acts as a protective ... to heal after injuries such as wounds and burns. ... situations in which foreign material is introduced, for example ...
(Date:8/22/2014)... tea polyphenols are strong antioxidants and can ... spinal cord neurons against oxidative stress? Jianbo ... Hospital of Liaoning Medical University, China discovered ... stress and inhibit neuronal apoptosis, indicating green ... spinal cord neurons under oxidative stress. The ...
Breaking Biology News(10 mins):Tissue regeneration using anti-inflammatory nanomolecules 2
... have won national awards for their research on the ... northern spotted owl. Martin Raphael and Eric Forsman, research ... Station, were named recipients of the Wings Across the ... the station,s Olympia, Wash., lab and Forsman at the ...
... barrier (BBB) remains a major obstacle to the successful ... disorders, reports Genetic Engineering and Biotechnology News ... approaches to preserve the ability of the BBB to ... and to permit the passage of effective medicines for ...
... plant pollen grains, sperm cells, which carry the genetic ... within larger "companion" cells that are called pollen vegetative ... nourishment, and push them towards their targets during fertilization. ... Spring Harbor Laboratory (CSHL) led by Professor Robert Martienssen, ...
Cached Biology News:Federal scientists recognized for contributions to knowledge of bird ecology and habitat 2GEN reports on strategies to overcome blood-brain barrier 2CSHL scientists discover how 'companion' cells to sperm protect them from genetic damage 2CSHL scientists discover how 'companion' cells to sperm protect them from genetic damage 3
... The kit measures mitochondria intactness ... mitochondrial membrane potential. Features and Benefits: ... method for staining isolated mitochondria and ... Contains all the reagents required for ...
... dispensers save space and organize ... and other garb. They are ... for small parts used in ... acrylic. Many other sizes and ...
... These handy dispensers save space and ... and other garb. They are the ... parts used in labs, processing and ... charges and the particles they attract. ...
... Microarrays designed for genome-wide microRNA ... flexible and powerful Paraflo microfluidic on-chip ... as part of our comprehensive microRNA ... Content The Mammals microRNA Microarray ...
Biology Products: